Published January 2004 | 560 Pages | 168 Exhibits | Forecasts Through 2008
All of our reports are available via individual purchase or as part of a subscription to our Medtech Pro platform, which includes a full library of reports.
Abiomed, Inc
Angiogene
Arrow International, Inc
Bioheart, Inc
BioSite, Inc.
Collateral Therapeutics, Inc.
Datascope Corporation
GenVec, Inc. (Diacrin, Inc.)
Guidant Corporation
Impulse Dynamics NV
Medtronic, Inc
Osiris Therapeutics, Inc.
St. Jude Medical, Inc
Thoratec Corporation
Vasomedical, Inc
WorldHeart Corporation
EXECUTIVE SUMMARY
Overview of Heart Failure
Diagnostic Testing
Rhythm Management Technologies
Ventricular Assist Devices
Other Mechanical Circulatory Support Technologies
Surgical and Other Approaches
Cell and Gene Therapy
Companies
Summary Exhibit 1: U.S. Market for Device-Based Heart Failure Technologies, 2002-2008
Summary Exhibit 2: U.S. Heart Failure Patient Forecast by Total Prevalence and NYHA Functional Classification, 2002-2008
Summary Exhibit 3: Penetration of Device-Based Therapies in the U.S. Heart Failure Population, 2002-2008
Summary Exhibit 4: U.S. Market for BNP Testing, 2002-2008
Summary Exhibit 5: U.S. Market for Rhythm Management Devices in Heart Failure, 2002-2008
Summary Exhibit 6: U.S. Market for Ventricular Assist Devices, 2002-2008
Summary Exhibit 7: U.S. Market for Mechanical Circulatory Support Technologies, 2002-2008
Summary Exhibit 8: U.S. Market for Surgical and Other Heart Failure Devices, 2002-2008
Summary Exhibit 9: U.S. Heart Failure Device Market, Supplier Shares, 2003
1.0 HEART FAILURE OVERVIEW
1.1 The Heart As A Pump
1.2 Definition of Heart Failure
1.3 Types of Heart Failure
1.4 Pathophysiology of Heart Failure
1.5 Clinical Manifestations of Heart Failure
1.6 Classification of Heart Failure
1.7 Epidemiology of Heart Failure
1.7.1 Etiology
1.7.1.1 Coronary Artery Disease
1.7.1.2 Hypertension
1.7.1.3 Cardiomyopathy
1.7.1.3.1 Dilated Cardiomyopathy
1.7.1.3.2 Hypertrophic Cardiomyopathy
1.7.1.3.3 Restrictive (Infiltrative) Cardiomyopathy
1.7.1.4 Valvular Heart Disease
1.7.1.5 Other Causes of Heart Failure
1.7.2 Risk Factors
1.7.3 Incidence & Prevalence
1.7.4 Mortality
1.7.5 Morbidity and Economic Impact
1.8 Diagnosis of Heart Failure
1.8.1 Scoring Systems
1.8.2 BNP Testing in Heart Failure
1.8.2.1 Economics of BNP testing
1.8.2.2 Suppliers
1.8.2.3 Market Analysis
1.9 Treatment of Heart Failure
1.10 Diastolic Heart Failure
Exhibit 1-1: The Heart as a Pump
Exhibit 1-2: Types of Heart Failure
Exhibit 1-3: Effects of neurohormonal agents on cardiac remodeling
Exhibit 1-4: Compensatory Mechanisms in Heart Failure
Exhibit 1-5: Adverse Effects of Compensatory Mechanisms in Heart Failure
Exhibit 1-6: Evolution of Our Understanding of Heart Failure and the Availability of Various Therapies
Exhibit 1-7: Common Symptoms of Heart Failure
Exhibit 1-8: NYHA Functional Classification of Heart Failure
Exhibit 1-9: ACC/AHA Classification of Heart Failure
Exhibit 1-10: Major Epidemiological Studies for Heart Failure in the U.S.
Exhibit 1-11: Etiology of Heart Failure
Exhibit 1-12: Risk factors and their relative risks for the development of HF
Exhibit 1-13: Summary of Results of Major Epidemiological Studies
Exhibit 1-14: Summary of U.S. Heart Failure Epidemiology
Exhibit 1-15: U.S. Heart Failure Patient Forecast by Total Prevalence and NYHA Functional Classification, 2002-2008
Exhibit 1-16: Survival After Heart Failure in the Framingham Heart Study
Exhibit 1-17: Historical Trends in U.S. Hospital Discharges for Heart Failure
Exhibit 1-18: Estimated Direct and Indirect Costs of Heart Failure
Exhibit 1-19: Sensitivity, Specificity, and Predictive Value of Symptoms, Signs and Chest X-Ray Findings for the Presence of Heart Failure
Exhibit 1-20: Scoring Systems for Heart Failure Diagnosis
Exhibit 1-21: Selected BNP Assays Available in the U.S., 2004
Exhibit 1-22: Non-Therapeutic/Diagnostic BNP Market, Supplier Shares, 2003
Exhibit 1-23: U.S. Patient and Market Forecast for BNP Tests, 2002-2008
Exhibit 1-24: Segmentation of the POC BNP Market, 2002-2008
Exhibit 1-25: Treatment Approaches and Their Impact on Pathophysiology of Heart Failure
Exhibit 1-26: ACC/AHA Guidelines for Heart Failure Treatment
Exhibit 1-27: Prevalence of Heart Failure with Preserved Systolic Function (Diastolic Heart Failure)
Exhibit 1-28: Correlation between age and gender in HFPSF/DHF
Exhibit 1-29: Mortality in Diastolic Heart Failure
Exhibit 1-30: Morbidity in Diastolic Heart Failure
Exhibit 1-31: Selected Ongoing Clinical Studies of Diastolic Heart Failure, 2004
2.0 RHYTHM MANAGEMENT IN HEART FAILURE
2.1 Cardiac Electrophysiology
2.1.1 Measuring the Heart’s Electrical Activity
2.1.2 Pathophysiology of Abnormal Electrical Timing
2.2 Cardiac Resynchronization Therapy (CRT)
2.2.1 Technique
2.2.2 Clinical Experience
2.2.3 Defibrillation in Heart Failure Patients
2.2.4 Indications/Contraindications
2.2.5 Limitations of CRT
2.2.6 Unanswered Issues with CRT
2.2.7 Products and Suppliers
2.2.7.1 Medtronic
2.2.7.1.1 CRTP
2.2.7.1.2 CRT-D
2.2.7.1.3 Leads and Delivery Systems
2.2.7.1.4 CareLink Network
2.2.7.2 Guidant
2.2.7.2.1 CRT-D
2.2.7.2.2 CRTP
2.2.7.2.3 Leads and Delivery Systems
2.2.7.3 St. Jude Medical
2.2.7.3.1 CRTP
2.2.7.3.2 Leads and Delivery Systems
2.2.7.3.3 CRT-D
2.2.7.4 Biotronik
2.2.7.5 ELA Medical
2.2.8 Potential Patient Population
2.2.9 Procedure Forecast
2.2.10 Market Analysis
2.3 Other Rhythm Management Approaches to Heart Failure
2.3.1 Stand Alone ICD Use
2.3.1.1 SCD-HeFT
2.3.1.2 Market Impact
2.3.2 Cardiac Contractility Modulation (Impulse Dynamics)
Exhibit 2-1: Overview of Rhythm Management Approaches to Heart Failure
Exhibit 2-2: Electric Conduction System of the Heart
Exhibit 2-3: Lead Positions for Biventricular Pacing
Exhibit 2-4: Early Observational Trials of Biventricular Pacing in Heart Failure
Exhibit 2-5: Major Biventricular Pacing Trials
Exhibit 2-6: Major Biventricular Pacing With ICD Trials
Exhibit 2-7: Effect of CRT on Various Heart Parameters
Exhibit 2-8: Effect of BVP/CRT on Mortality and Morbidity
Exhibit 2-9: Selected CRT Products and Suppliers, 2004
Exhibit 2-10: Medtronic's CRT Products
Exhibit 2-11: Guidant's CRT Products
Exhibit 2-12: St. Jude Medical's CRT Products
Exhibit 2-13: Biotronik's CRT Products
Exhibit 2-14: Potential U.S. Patient Population for Cardiac Resynchronization Therapy, 2002-2008
Exhibit 2-15: U.S. Procedure and Market Forecast for Cardiac Resynchronization Therapy, 2002-2008
Exhibit 2-16: CRT Market Shares, 2003
Exhibit 2-17: SCDHeFT Results - Hazard Ratios & All Cause Mortality
Exhibit 2-18: SCD HeFT Results - Subgroup Analyses
Exhibit 2-19: Potential Patient Population for Stand Alone ICD Therapy in Heart Failure, 2002-2008
Exhibit 2-20: Procedure and Market Forecast for Stand Alone ICD Therapy in Heart Failure, 2002-2008
Exhibit 2-21: Impulse Dynamic's Optimizer System
3.0 VENTRICULAR ASSIST DEVICES
3.1 VAD Types
3.1.1 Implantation
3.1.1.1 External VADs
3.1.1.2 Internal VADs
3.1.1.3 Percutaneous VADs
3.1.2 Pump Type
3.1.2.1 Pulsatile Flow
3.1.2.2 Continuous Flow
3.1.2.2.1 Axial
3.1.2.2.2 Centrifugal
3.1.3 Device Selection
3.2 VAD Indications
3.2.1 Bridge to Recovery
3.2.2 Bridge To Transplant
3.2.3 Destination Therapy
3.2.4 Therapeutic Recovery
3.3 VAD Contraindications
3.4 Clinical Experience
3.4.1 Patient Selection
3.4.2 Specific Complications
3.4.3 REMATCH
3.5 Products and Suppliers
3.5.1 Abiomed
3.5.2 A-Med Systems
3.5.3 Arrow International
3.5.3.1 LionHeart LVAS
3.5.3.2 CorAide
3.5.4 Berlin Heart
3.5.4.1 EXCOR
3.5.4.2 INCOR
3.5.5 Biomedlab Company
3.5.6 CardiacAssist
3.5.6.1 AB-180 iVAD
3.5.6.2 TandemHeart PTVA
3.5.7 Cardianove
3.5.8 Gold Medical Technologies
3.5.9 Impella CardioSystems
3.5.9.1 impella recover
3.5.9.2 impella acute
3.5.9.3 impella mobile console
3.5.10 Intra-Vasc
3.5.11 Jarvik Heart
3.5.12 Levitronix
3.5.13 MedQuest Products
3.5.14 MicroMed Technology
3.5.14.1 Device Description
3.5.14.2 Regulatory Status
3.5.14.3 Clinical Experience
3.5.14.4 Chrysalis
3.5.15 MiTi Heart
3.5.16 Terumo Heart
3.5.17 Thoratec
3.5.17.1 Thoratec VAD
3.5.17.1.1 TLC-II
3.5.17.1.2 Thoratec IVAD
3.5.17.2 HeartMate LVAS
3.5.17.2.1 HeartMate IP
3.5.17.2.2 HeartMate VE
3.5.17.2.3 HeartMate II
3.5.17.2.4 HeartMate III
3.5.18 Ventracor
3.5.19 WorldHeart
3.5.19.1 Novacor LVAS
3.5.19.1.1 Device Description
3.5.19.1.2 Clinical Experience
3.5.19.1.3 Regulatory Status
3.5.19.1.4 Pricing/Distribution
3.5.19.2 Next Generation LVAS
3.6 Market Analysis
3.6.1 Reimbursement
3.6.2 Procedure Forecast
3.6.2.1 Post-Cardiotomy
3.6.2.2 Bridge To Transplant
3.6.2.3 Destination Therapy
3.6.2.4 Future Considerations
3.6.3 Market Analysis
3.6.3.1 Post-Cardiotomy
3.6.3.2 Bridge To Transplant
3.6.3.3 Destination Therapy
3.6.4 Competitive Analysis
Exhibit 3-1: Overview of Mechanical Circulatory Assist Options
Exhibit 3-2: Types of Ventricular Assist Devices.
Exhibit 3-3: Importance of VAD Attributes by Potential Patient Population
Exhibit 3-4: Classification of Mechanical Circulatory Support Devices According to Disease Severity
Exhibit 3-5: Overview of VAD Indications
Exhibit 3-6: Considerations for VAD Patient Selection
Exhibit 3-7: Overview of REMATCH Study Results
Exhibit 3-8: Selected External Ventricular Assist Products and Suppliers, 2004
Exhibit 3-9: Selected Implantable Ventricular Assist Products and Suppliers, 2004
Exhibit 3-10: Selected Percutaneous Ventricular Assist Products and Suppliers, 2004
Exhibit 3-11: Abiomed's VAD Products
Exhibit 3-12: A-Med Systems' pLVAD
Exhibit 3-13: Arrow International's VAD Products
Exhibit 3-14: Berlin Heart's VAD Products
Exhibit 3-15: Biomedlab's AnyHeart BiVAD
Exhibit 3-16: CardiacAssist's VAD Products
Exhibit 3-17: Impella CardioSystems' VAD Products
Exhibit 3-18: Positioning of Intra-Vasc's PUCA-pump (LVAD Configuration)
Exhibit 3-19: Jarvik Heart's Jarvik 2000 Flowmaker
Exhibit 3-20: Levitronix' CentriMag Extracorporeal Blood Pumping System
Exhibit 3-21: MedQuest Products' HeartQuest VAD
Exhibit 3-22: MicroMed Technology's DeBakey VAD
Exhibit 3-23: Terumo's DuraHeart LVAS
Exhibit 3-24: The Thoratec VAD System
Exhibit 3-25: Thoratec's HeartMate Product Line
Exhibit 3-26: Ventracor's VentrAssist LVAS
Exhibit 3-27: WorldHeart's Novacor LVAS
Exhibit 3-28: WorldHeart's Next Generation LVAS
Exhibit 3-29: The History of VAD Medicare Reimbursement
Exhibit 3-30: VAD-Related CPT Codes & Physician Payments
Exhibit 3-31: U.S. Procedure Forecast for Ventricular Assist Devices, 2002-2008
Exhibit 3-32: U.S. Market for Ventricular Assist Devices, 2002-2008
Exhibit 3-33: U.S. Market for Ventricular Assist Devices by Device Type, 2003 & 2008
Exhibit 3-34: U.S. Supplier Shares for Ventricular Assist Devices, 2002-2003
Exhibit 3-35: Implantable VAD Supplier Shares, 2002-2003
Exhibit 3-36: External VAD Supplier Shares, 2002-2003
4.0 OTHER MECHANICAL CIRCULATORY SUPPORT TECHNOLOGIES
4.1 External Counterpulsation
4.1.1 Technique
4.1.2 Indications
4.1.3 Contraindications and Complications
4.1.4 Reimbursement
4.1.5 Product Description
4.1.6 Clinical Experience
4.1.6.1 Angina Pectoris
4.1.6.2 Heart Failure
4.1.6.3 Mechanisms of Action
4.1.7 Products and Suppliers
4.1.7.1 Cardiomedics
4.1.7.2 CPC of America
4.1.7.3 Living Data Technology Corp.
4.1.7.4 Nicore
4.1.7.5 Vasomedical
4.1.8 Product Trends
4.1.9 Market Analysis
4.2 Intra-Aortic Balloon Pumps
4.2.1 Technology and Usage
4.2.2 Indications and Contraindications
4.2.3 Potential Complications
4.2.4 Product Trends
4.2.5 Products and Suppliers
4.2.5.1 Datascope
4.2.5.2 Arrow International
4.2.6 Market Analysis
4.3 Cardiac Recovery Systems
4.3.1 Indications
4.3.2 Products and Suppliers
4.3.2.1 Orqis Medical
4.3.2.2 CardiO2 (JOMED)
4.3.3 Market Analysis
4.4 Total Artificial Hearts
4.4.1 History
4.4.2 Indications
4.4.3 Products and Suppliers
4.4.3.1 Abiomed
4.4.3.1.1 Device Description
4.4.3.1.2 Clinical Experience
4.4.3.1.3 Cost Effectiveness
4.4.3.1.4 Regulatory Status
4.4.3.1.5 AbioCor II
4.4.3.2 SynCardia Systems
4.4.3.2.1 Device Description
4.4.3.2.2 Clinical Experience
4.4.3.2.3 Regulatory Status
4.4.3.2.4 Pricing/Distribution
4.4.3.3 Other Programs
4.4.3.3.1 Tohoku University
4.4.3.3.2 University of Tokyo
4.4.3.3.3 Vacord Bioengineering Research Company
4.4.4 Market Analysis
4.4.4.1 Bridge To Transplant
4.4.4.2 Destination Therapy
4.5 Cardiac Compression
4.5.1 Products
4.5.1.1 Abiomed
4.5.1.2 CardioEnergetics
4.5.1.3 Cardio Technologies
4.5.2 Market Analysis
4.6 Counterpulsating Ventricular Assist Technologies
4.6.1 Intra-Aortic Ventricular Assist Device (CardioVad)
4.6.1.1 Design and Implantation
4.6.1.2 Operation and Benefits
4.6.1.3 Clinical Experience
4.6.1.4 Commercialization Plans
4.6.2 Extra-Aortic Counterpulsation Devices
4.6.2.1 Harefield Cardiac
4.6.2.2 Sunshine Heart
4.6.3 Market Analysis
Exhibit 4-1: Overview Mechanical Circulatory Support Technologies
Exhibit 4-2: Schematic of Extracorporeal Counterpulsation
Exhibit 4-3: Indications and Contraindications for ECP
Exhibit 4-4: Selected External Counterpulsation Therapy Systems in Use
Exhibit 4-5: Potential Mechanisms for Clinical Effectiveness of ECP
Exhibit 4-6: Selected External Counterpulsation Systems, 2004
Exhibit 4-7: External Counterpulsation, Patient and Market Forecast, 2002-2008
Exhibit 4-8: External Counterpulsation Systems, Supplier Shares, 2003
Exhibit 4-9: Indications & Contraindications for IABP Therapy
Exhibit 4-10: Benchmark Registry: Indications for IABP Therapy
Exhibit 4-11: Benchmark Registry: Complications Associated with IAPB Therapy
Exhibit 4-12: Selected Intra-Aortic Balloon Pump Products, 2004
Exhibit 4-13: Datascope CS100 Controller and Fidelity Catheter
Exhibit 4-14: Arrow International AutoCAT 2 WAVE and Light WAVE Catheter
Exhibit 4-15: Intra-Aortic Balloon Pumps and Controllers, Market Forecast, 2002-2008
Exhibit 4-16: Intra-Aortic Balloon Pumps, Supplier Shares, 2003
Exhibit 4-17: Cardiac Recovery Systems, Products and Suppliers, 2004
Exhibit 4-18: Orqis Medical's Cancion Cardiac Recovery System
Exhibit 4-19: CardiO2's Reitan Catheter Pump
Exhibit 4-20: U.S. Market for Cardiac Recovery Systems, 2004-2008
Exhibit 4-21: Selected Total Artificial Heart Programs, 2004
Exhibit 4-22: Abiomed's AbioCor Implantable Replacement Heart
Exhibit 4-23: SynCardia Systems' CardioWest Total Artificial Heart
Exhibit 4-24: Selected Clinical Outcomes of the CardioWest Total Artificial Heart
Exhibit 4-25: Selected Development Stage TAH Devices
Exhibit 4-26: U.S. Procedure Forecast for Total Artificial Hearts, 2003-2008
Exhibit 4-27: U.S. Market Forecast for Total Artificial Hearts, 2003-2008
Exhibit 4-28: Selected Cardiac Compression Devices, 2004
Exhibit 4-29: CardioEnergetics' RePower Device
Exhibit 4-30: Selected Counterpulsating Ventricular Assist Technologies, 2004
Exhibit 4-31: Kantrowitz CardioVad Counterpulsating Ventricular Assist Device
Exhibit 4-32: Harefield Cardiac AK-Pulsator
Exhibit 4-33: Sunshine Heart Extra-Aortic Balloon Counterpulsation Device
Exhibit 4-34: Counterpulsating Ventricular Assist Devices, Patient and Market Forecast 2007-2008
5.0 SURGICAL AND OTHER APPROACHES
5.1 Cardiac Transplantation
5.1.1 Cardiac Transplant Statistics
5.1.2 Transplant Forecast
5.2 Dynamic Cardiomyoplasty
5.2.1 Patient Indications
5.2.2 Risk Factors
5.2.3 Clinical Outcomes
5.2.4 Limitations
5.3.5 Emerging Protocols
5.2.6 ACC/AHA Guidelines and Clinical Prospects
5.2.7 Products and Suppliers
5.2.7.1 Medtronic
5.2.7.2 Pacetronic Corporation
5.2.8 Market Analysis
5.3 Left Ventricular Volume Reduction
5.3.1 Procedure
5.3.2 Indications
5.3.3 Clinical Outcomes
5.3.4 Procedure Volume
5.4 Ventricular Reconstruction and Restoration
5.4.1 Techniques
5.4.1.1 Endovascular Circular Patch Plasty
5.4.1.2 Septal Anterior Ventricular Exclusion
5.4.2 Surgical Ventricular Restoration
5.4.2.1 Clinical Experience (RESTORE and STICH Trials)
5.4.2.2 SVR Products
5.4.2.2.1 Chase Medical
5.4.2.2.2 CHF Technologies
5.4.2.2.3 Somanetics
5.4.2.3 Procedure Trend
5.4.2.4 Market Analysis
5.5 Less Invasive Surgical Cardiac Support
5.5.1 Acorn Cardiovascular
5.5.2 CardioEnergetics/CardioClasp
5.5.3 Myocor
5.5.4 Paracor Medical
5.5.5 Procedure and Market Forecast
5.6 Percutaneous Mitral Valve Repair and Replacement
5.6.1 Percutaneous Annuloplasty
5.6.2 Percutaneous Valve Repair
5.6.3 Percutaneous Valve Replacement
5.6.4 Products and Suppliers
5.7 Device-Based Fluid Reduction Strategies
5.7.1 Potential Risks of Chronic Diuretic Therapy
5.7.2 Device-Based Fluid Reduction
5.7.2.1 Ultrafiltration (CHF Solutions)
5.7.2.1.1 System100 Components
5.7.2.1.2 Clinical Experience
5.7.2.1.3 Pricing and Reimbursement
5.7.2.2 Active Renal Infusion (FlowMedica)
5.7.2.2.1 Benephit Infusion System
5.7.2.2.2 Indications
5.7.2.2.3 Application to Heart Failure
5.7.2.2.4 Clinical Experience
5.7.2.2.5 Company Background
5.7.2.3 Patient Trend and Market Analysis
Exhibit 5-1: Indications for Cardiac Transplantation
Exhibit 5-2: Selected Cardiac Transplant Data, 1995 and 2003
Exhibit 5-3: Historical Trend in Cardiac Transplant Procedures, 1994-2003
Exhibit 5-4: Cardiac Transplants, Procedure Forecast, 2002-2008
Exhibit 5-5: Selected Cardiomyostimulators for Dynamic Cardiomyoplasty, 2004
Exhibit 5-6: Potential Roll Out Scenario for Demand Cardiomyostimulator Market, 2006-2008
Exhibit 5-7: Selected Surgical Ventricular Restoration Systems, 2004
Exhibit 5-8: Chase Medical TR3ISVR System
Exhibit 5-9: TR3ISVR Procedure
Exhibit 5-10: CHF Technologies' CHFT Sizer/Shaper and Patch
Exhibit 5-11: Somanetics' CorRestore Patch Implant
Exhibit 5-12: Area Map of HF Patients, Major Causes and Selected Therapies
Exhibit 5-13: Surgical Ventricular Restoration, Procedure and Market Forecast, 2002-2008
Exhibit 5-14: SVR Systems, Supplier Shares, 2003
Exhibit 5-15: Selected Minimally Invasive Surgical Cardiac Support Devices, 2004
Exhibit 5-16: Acorn Cardiovascular CorCap Cardiac Support Device
Exhibit 5-17: CardioClasp Device
Exhibit 5-18: Myocor Myosplint Device
Exhibit 5-19: Minimally Invasive Surgical Cardiac Support, Procedure & Market Forecast, 2002-2008
Exhibit 5-20: Percutaneous Approaches to Valve Disease Management
Exhibit 5-21: Selected Percutaneous Valve Repair and Replacement Programs, 2004
Exhibit 5-22: Selected Device-Based Fluid Reduction Technologies, 2004
Exhibit 5-23: CHF Solutions' System 100
Exhibit 5-24: FlowMedica Benephit Infusion System
Exhibit 5-25: Device-Based Fluid Reduction, Market Forecast, 2002-2008
6.0 CELL AND GENE THERAPY
6.1 Cell Transplantation Therapy
6.1.1 Approaches
6.1.1.1 Cardiomyocytes
6.1.1.2 Skeletal Myoblasts
6.1.1.3 Stem cells
6.1.2 Products and Suppliers
6.1.2.1 Advanced Cell Technology
6.1.2.2 Angiogene
6.1.2.3 BioCardia
6.1.2.4 Bioheart
6.1.2.5 Cell Transplants International
6.1.2.6 Diacrin (GenVec)
6.1.2.7 Genzyme Biosurgery
6.1.2.8 Medtronic
6.1.2.9 Osiris Therapeutics
6.1.3 Market Potential
6.2 Gene Therapy
6.2.1 Vectors for Gene Delivery
6.2.2 Mechanisms of Cardiac Gene Delivery
6.2.3 Gene Therapy Programs to Treat Heart Failure
6.2.4 Therapeutic Angiogenesis
6.2.5 Future Directions of Gene Therapy
Exhibit 6-1: Approaches to Heart Failure Cell Transplantation
Exhibit 6-2: Selected Human Clinical Studies of Skeletal Myoblast-Based Cardiac Cell Transplantation
Exhibit 6-3: Incidence of Arrhythmia in Cardiac Cell Transplantation
Exhibit 6-4: Selected Animal Studies Evaluating Cardiac Stem Cell Transplantation
Exhibit 6-5: Advantages and Disadvantages of Various Approaches in Cardiac Cell Transplantation Therapy
Exhibit 6-6: Selected Human Clinical Studies of Cardiac Stem Cell Transplantation
Exhibit 6-7: Selected Cell Based Therapies for Heart Failure, 2004
Exhibit 6-8: U.S. Procedure and Market Forecast for Cardiac Cell Transplantation, 2007-2008
Exhibit 6-9: Properties of Vector Systems for Gene Transfer
Exhibit 6-10: Approaches to Cardiac Gene Delivery
Exhibit 6-11: Selected U.S. Gene Therapy Programs Related to Heart Failure, 2004
Exhibit 6-12: Selected Angiogenesis Programs for Ischemic/Coronary Heart Disease, 2004
7.0 COMPANY PROFILES*
7.1 Abiomed, Inc
7.2 Angiogene
7.3 Arrow International, Inc
7.4 Bioheart, Inc
7.5 BioSite, Inc.
7.6 Collateral Therapeutics, Inc.
7.7 Datascope Corporation
7.8 GenVec, Inc. (Diacrin, Inc.)
7.9 Guidant Corporation
7.10 Impulse Dynamics NV
7.11 Medtronic, Inc
7.12 Osiris Therapeutics, Inc.
7.13 St. Jude Medical, Inc
7.14 Thoratec Corporation
7.15 Vasomedical, Inc
7.16 WorldHeart Corporation
* Note: Numerous small competitors are profiled in their technology descriptions.
APPENDIX: COMPANY LIST
We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
